首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
admin
2013-11-29
61
问题
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea: the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy, diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. "We’ve been too rigid in not making lifesaving drugs available to people who otherwise face certain death," says Representative Henry Waxman, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’s true of AIDS, but it’s also true of cancer and other life- threatening diseases."
For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story: a crisis—AIDS—helped crystallize an informal coalition for reform.
AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Do, g Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs—those that show new promise in treating serious or life-threatening diseases— had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it pro- posed died in Congress. Complaints were compounded by growing concern that "if we didn’t streamline policies, red tape wot, Id be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
Young was a key figure in the overhaul of the FDA’s policies. A pioneer in biotechnology and a former dean of the University of Rochester’s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology-- whose promise he had seen in his own gene-cloning lab--and to get experimental medicines to desperately iii people more quickly. He had seen people die waiting for new medicines because "they were in the wrong place at the wrong time," he said. That is now changing.
During his tenure of office as head of the FDA, Frank E. Young______.
选项
A、had a bitter argument with his colleagues over the overhaul of drug-approval policies
B、played a leading role in reconstructing the FDA’s policies
C、made some efforts to overhaul drug-approval policies, but failed
D、met many difficulties in releasing breakthrough drugs to the desperately iii patients
答案
B
解析
转载请注明原文地址:https://kaotiyun.com/show/cHhO777K
0
考博英语
相关试题推荐
ThedomesticeconomyintheUnitedStatesexpandedinaremarkablyvigorousandsteadyfashion.Therevivalinconsumerconfiden
Thelawofprivateinternationaltribunalswithrespecttoconflictsofinterestofarbitratorsisquiteextensive,albeitbyno
Justiceinsocietymustincludebothafairtrialtotheaccusedandtheselectionofanappropriatepunishmentforthoseproven
Variousinnovationshavebeenintroducedaswaystobreakoffoursystemwhichforcesstudentsthroughaseriesofidenticalcla
Inrecentyears,railroadshavebeencombiningwitheachother,mergingintosupersystems,causingheightenedconcernsaboutmo
Thedramacritic,ontheotherhand,hasnosuchadvantage.Hecannotbeselective;hemustcovereverythingthatisofferedfor
Thedramacritic,ontheotherhand,hasnosuchadvantage.Hecannotbeselective;hemustcovereverythingthatisofferedfor
Changingfromsolidtoliquid,watertakesinheatfromallsubstancesnearit,andthis______producesartificialcoldsurroun
AstothelostworldofEgypt,weknownearlyeverything______toknow.
随机试题
下列对类的声明,正确的是()。
下列选项不适用《企业破产法》的是
欲正其心者,__________。
阅读苏轼《前赤壁赋》中的文字:苏子曰:“客亦知夫水与月乎?逝者如斯,而未尝往也;盈虚者如彼,而卒莫消长也。盖将自其变者而观之,则天地曾不能以一瞬;自其不变者而观之,则物与我皆无尽也,而又何羡乎?且夫天地之间,物各有主,苟非吾之所有,虽一
常规临床工作中所测得的RF类型是
腹部检查时,胃型常见于
10个月小儿,阵发性哭闹,伴呕吐,黏液血便,右下腹可触及腊肠样包块,最可能的诊断
描述一组正态分布资料的变异度,较适用的指标是
在某赈灾募捐活动中,某牛奶企业捐赠了价值数万元的酸奶。在运送酸奶到灾区的途中,因交通中断,滞留在某地,即将变质。此种情形下,下列处理方式符合相关规定的是()。[2009年真题]
体现教育外部关系规律的是()。
最新回复
(
0
)